Xenetic Biosciences, Inc. 10-K

ITEM 5 – MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES Our common stock and common stock purchase warrants are listed on The Nasdaq Capital Market (“Nasdaq”) under the symbols “XBIO” and “XBIOW”, respectively. Holders of Record As of March 18, 2022, there were 424 holders of record of our common stock. Dividends We have never previously declared or paid any cash dividends on our common stock. We currently intend to retain earnings and profits, if any, to support our business strategy and do not intend to pay any cash dividends within the foreseeable future. Any future determination to pay cash dividends will be at the sole discretion of our Board of Directors and will depend upon the financial condition of the Company, our operating results, capital requirements, general business conditions and any other factors that the Board of Directors deems relevant. Equity Compensation Plan Information The information required by Item 5 with respect to securities authorized for issuance under equity compensation plans is incorporated herein by reference to Part III, Item 12 of this Form 10-K. Recent Sales of Unregistered Securities None. Repurchases of Equity Securities of the Issuer During the quarter ended December 31, 2021, we did not repurchase any of our outstanding shares of common stock. ITEM 6 – [RESERVED] Reserved.